Side Effects of atogepant: A Synthesis of Findings from 4 Studies

  1. Home
  2. Side Effects of atogepant
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of atogepant: A Synthesis of Findings from 4 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of atogepant: A Synthesis of Findings from 4 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Atogepant is a new drug effective in preventing and treating acute migraines. 2

Atogepant is a CGRP receptor antagonist that has been shown in clinical trials to be effective in preventing and treating acute migraines. 2

Atogepant has been found to be less hepatotoxic compared to other CGRP antagonists. 3

Atogepant has been found to have fewer side effects compared to other CGRP antagonists. 2

Reasons for Side Effects

The side effects of atogepant are due to its binding to the CGRP receptor. 2

Common Side Effects

Frequency Unknown

Atogepant has been found to have fewer side effects compared to other CGRP antagonists. 2

Side Effect Management

To reduce side effects of atogepant, it is important to take it as prescribed by your doctor. 2

If you are concerned about side effects of atogepant, please consult your doctor. 2

Comparison Between Studies

Commonalities

Atogepant is a new drug effective in preventing and treating acute migraines. 2

Atogepant has been found to be less hepatotoxic compared to other CGRP antagonists. 3

Differences

Atogepant has been found to have fewer side effects compared to other CGRP antagonists. 2

Precautions for Real-Life Applications

Atogepant is a new drug effective in preventing and treating acute migraines. 2

Atogepant has been found to be less hepatotoxic compared to other CGRP antagonists. 3

Atogepant has been found to have fewer side effects compared to other CGRP antagonists. 2

Limitations of Current Research

Long-term side effects of atogepant have not been adequately studied. 2

Safety and efficacy of atogepant in the elderly and pregnant women have not been fully evaluated. 2

Future Research Directions

Research is needed to evaluate the long-term side effects of atogepant. 2

Research is needed to evaluate the safety and efficacy of atogepant in the elderly and pregnant women. 2

Conclusion

Atogepant is a new drug effective in preventing and treating acute migraines. 2

Atogepant has been found to be less hepatotoxic compared to other CGRP antagonists. 3

Atogepant has been found to have fewer side effects compared to other CGRP antagonists. 2

Research is needed to evaluate the long-term side effects of atogepant. 2

Research is needed to evaluate the safety and efficacy of atogepant in the elderly and pregnant women. 2

Literature analysis of 4 papers
Positive Content
4
Neutral Content
0
Negative Content
0
Article Type
1
0
0
2
4
1.

Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.

Author: SinghBramah N, ConnollyStuart J, CrijnsHarry J G M, RoyDenis, KoweyPeter R, CapucciAlessandro, RadzikDavid, AliotEtienne M, HohnloserStefan H,

Reduced ventricular rate
Sinus rhythm maintenance
Pulmonary toxic effects
Thyroid and liver dysfunction

Dronedarone was significantly more effective than placebo in maintaining sinus rhythm and reducing ventricular rate during recurrence of arrhythmia. There was no evidence that dronedarone increased the risk of pulmonary toxicity, thyroid dysfunction, or liver dysfunction.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

Gepants for Acute and Preventive Migraine Treatment: A Narrative Review.

Author: RissardoJamir Pitton, CapraraAna Letícia Fornari

Migraine prevention
Hemodynamic impairment

The new generation of CGRP antagonists, including rimegepant, ubrogepant, atogepant, and zavegepant, are effective for the acute and/or preventive treatment of migraines. While generally well-tolerated, long-term safety concerns remain, and careful pharmacovigilance is crucial. Further research is needed to assess their long-term effects and compare them with triptans, especially in elderly populations.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

4.

The role of erenumab in the treatment of migraine.

Author: AndreouAnna P, FuccaroMatteo, LambruGiorgio

Improved quality of life
Migraine prevention
Reduced disability
Discontinuation rate
Side effects

CGRP monoclonal antibodies (mAbs) are a new class of drugs for preventing migraine headaches. This review focuses on erenumab, a CGRP mAb that is the first in its class to be approved by the US Food and Drug Administration. The review summarizes erenumab's characteristics, clinical trial data, and its potential role in clinical practice.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.